Authors: Z. Adam 1; Z. Fojtík 2; Z. Řehák 3; V. Kubeš 4; M. Tomíška 1; A. Vojvodová 5; K. Svobodová 6; I. Boichuk 1; M. Krejčí 1; Z. Chovancová 7; T. Horváth 8; M. Borský 1; R. Koukalová 3; L. Pour 1 Authors‘ workplace: Interní hematologická a onkologická klinika LF MU a FN Brno 1; Diagnosticko-terapeutické centrum, revmatologická ambulance, FN Brno 2; Oddělení nukleární medicíny, Masarykův onkologický ústav, Brno 3; Ústav patologie LF MU a FN Brno 4; Klinika radiologie a nukleární medicíny, LF MU a FN Brno 5; Oddělení otorhinolaryngologie, FN Brno 6; Ústav klinické imunologie a alergologie LF MU a FN u sv. Anny v Brně 7; Chirurgická klinika LF MU a FN Brno 8 Published in: Klin Onkol 2025; 38(6): 447-463 Category: Original Articles doi: https://doi.org/10.48095/ccko2025447
Background: Polyclonal hypergammaglobulinemia has a variety of causes, which we outline in the text. Regularly, very high concentrations of polyclonal immunoglobulins are observed in IgG4-related disease, Sjögren’s syndrome, and in the idiopathic multicentric Castleman disease. Observation: We describe a patient who had induration of the salivary glands and an immunoglobulin IgG level of 42 g/l. Over the course of 3 months from the first contact, there was a significant overall deterioration: skin rash presumably due to vasculitis, impaired kidney function with pathological proteinuria, exophthalmus, and heart failure. Increased concentration of subclass immunoglobulin IgG4, along with histological assessment of the excised salivary gland, led to the diagnosis of a IgG4 related disease. Results: The treatment was started with prednisone, which very soon led to the manifestation of diabetes mellitus, and therefore we requested approval for rituximab from the healthcare payer. We chose a regimen in which the effect of rituximab is further potentiated by adding cyclophosphamide and dexamethasone. The patient received 6 cycles consisting of rituximab 800 mg on the 1st day of the cycle. Additionally, dexamethasone 20 mg and cyclophosphamide 600 mg were administered on the 1st and 15th days of the 28-day cycle. The treatment led to a complete remission, with duration for 24 months at the time of evaluation. The patient is scheduled for maintenance treatment with rituximab 1,000 mg infused at 6-month intervals, but we extend these intervals if the disease markers (the concentration of IgG4 subclass immunoglobulin and the number of circulating plasmablasts in peripheral blood) are completely normal. Conclusion: The Mikulicz phenotype of the IgG4-related disease is characterized not only by the involvement of exocrine glands but also by damage to other organs (kidneys, cardiovascular system and skin). This disease tends to progress rapidly if not timely halted with effective treatment, in our case a combination of rituximab with a low dose of cyclophosphamide. Cyclophosphamide has the potential in this disease not only to potentiate glucocorticoid therapy, but our experience confirms published data that it enhances the effect of rituximab and presumably also prolongs the duration of the treatment response.
rituximab – obinutuzumab – IgG4-related disease – Sjögren’s syndrome – polyclonal hypergammaglobulinemia – Mikulicz’s disease – idiopathic multicentric Castleman disease
1. Betrains A, Staels F, Schrijvers R et al. Systemic autoinflammatory disease in adults. Autoimmun Rev 2021; 20 (4): 102774. doi: 10.1016/j.autrev.2021.102774.
2. Fajgenbaum DC, Uldrick TS, Bagg A et al. International, evidence-based consensus diagnostic criteria for HHV--8-negative/idiopathic multicentric Castleman disease. Blood 2017; 129 (12): 1646–1657. doi: 10.1182/blood-2016-10-746933.
3. Umehara H, Okazaki K, Kawa S et al. The 2020 revised comprehensive diagnostic (RCD) criteria for IgG4-RD. Mod Rheumatol 2021; 31 (3): 529–533. doi: 10.1080/143 97595.2020.1859710.
4. Umehara H, Okazaki K, Nakamura T et al. Current approach to the diagnosis of IgG4-related disease – combination of comprehensive diagnostic and organ-specific criteria. Mod Rheumatol 2017; 27 (3): 381–391. doi: 10.1080/14397595.2017.1290911.
5. Wallace ZS, Naden RP, Chari S et al. The 2019 American College of Rheumatology/European League Against Rheumatism classification criteria for IgG4-related disease. Ann Rheum Dis 2020; 79 (1): 77–87. doi: 10.1136/annrheumdis-2019-216561.
6. Adam Z, Zeman D, Čermák A et al. IgG4-related disease. Clinical manifestation differential diagnosis and recent International Diagnostic Criteria for IgG4-related disease. Vnitr Lek 2022; 68 (E-5): 4–19. doi: 10.36290/vnl. 2022.070.
7. Shiboski CH, Shiboski SC, Seror R et al. 2016 American College of Rheumatology/European League Against Rheumatism classification criteria for primary Sjögren’s syndrome: a consensus and data-driven methodology involving three international patient cohorts. Ann Rheum Dis 2017; 76 (1): 9–16. doi: 10.1136/annrheumdis-2016-210571.
8. Červeňáková K, Procházková L, Červeňák V. Sjögrenův syndrom. Alergie 2020; 22 (2): 105–109.
9. Sasaki T, Akiyama M, Kaneko Y et al. Immunoglobulin G4-related disease and idiopathic multicentric Castleman’s disease: confusable immune-mediated disorders. Rheumatology (Oxford) 2022; 61 (2): 490–501. doi: 10.1093/rheumatology/keab634.
10. Sun C, Xu G, Lin J. Comparison of IgG4-related lymphadenopathy and multicentric Castleman’s disease: a retrospective study. Clin Lab 2018; 64 (10): 1671–1678. doi: 10.7754/Clin.Lab.2018.180421.
11. Masaki Y, Sugai S, Umehara H. IgG4-related diseases including Mikulicz’s disease and sclerosing pancreatitis: diagnostic insights. J Rheumatol 2010; 37 (7): 1380–1385. doi: 10.3899/jrheum.091153.
12. Izumi Y, Takeshita H, Moriwaki Y et al. Multicentric Castleman disease mimicking IgG4-related disease: a case report. Mod Rheumatol 2017; 27 (1): 174–177. doi: 10.3109/14397595.2014.985356.
13. Otani K, Inoue D, Fujikura K et al. Idiopathic multicentric Castleman’s disease: a clinicopathologic study in comparison with IgG4-related disease. Oncotarget 2018; 9 (6): 6691–6706. doi: 10.18632/oncotarget.24068.
14. Yoshimi R, Nakajima H. Idiopathic multicentric Castleman’s disease as a mimicker of IgG4-related disease. Intern Med 2025; 64 (12): 1788–1790. doi: 10.2169/internalmedicine.4793-24.
15. Li N, Xu L, Liu X et al. Castleman disease misdiagnosed as immunoglobulin G4-related disease: a case report. Front Immunol 2025; 16 : 1532627. doi: 10.3389/fimmu.2025.1532627.
16. Manger B, Schett G. Jan Mikulicz-Radecki (1850–1905): return of the surgeon. Ann Rheum Dis 2021; 80 (1): 8–10. doi: 10.1136/annrheumdis-2020-218843.
17. Hong X, Li W, Xie XY et al. Differential diagnosis of IgG4-related sialadenitis, primary Sjögren syndrome, and chronic obstructive submandibular sialadenitis. Br J Oral Maxillofac Surg 2017; 55 (2): 179–184. doi: 10.1016/j.bjoms.2016.10.021.
18. Qin Y, Shang L, Wang Y et al. Immune profile differences between IgG4-related diseases and primary Sjögren’s syndrome. J Inflamm Res 2025; 18 : 911–923. doi: 10.2147/JIR.S471266.
19. Ren T, Liu R, Li J et al. Primary Sjögren’s syndrome misdiagnosed as Mikulicz’s disease: a case report. BMC Ophthalmol 2023; 23 (1): 336. doi: 10.1186/s12886-023-03090-1.
20. Otani Y, Shimura T, Nogaki T et al. Differentiation between IgG4-related Mikulicz disease and Sjögren’s syndrome: a review case report and literature review. Medicine (Baltimore) 2022; 101 (52): e32617. doi: 10.1097/MD.0000000000032617.
21. Mahmoud R, Ianculovici C, Kleinman S et al. IgG4-related sialadenitis – a rare bilateral submandibular gland enlargement: case report. Oral Maxillofac Surg 2022; 26 (4): 673–677. doi: 10.1007/s10006-021-01020-3.
22. Aboulenain S, Miquel TP, Maya JJ. Immunoglobulin G4 (IgG4) -related sialadenitis and dacryoadenitis with chronic rhinosinusitis. Cureus 2020; 12 (8): e9756. doi: 10.7759/cureus.9756.
23. Shimizu M, Okamura K, Kise Y et al. Effectiveness of imaging modalities for screening IgG4-related dacryoadenitis and sialadenitis (Mikulicz’s disease) and for differentiating it from Sjögren’s syndrome (SS), with an emphasis on sonography. Arthritis Res Ther 2015; 17 (1): 223. doi: 10.1186/s13075-015-0751-x.
24. Adam Z, Pour L, Zeman D a kol. Vzácné choroby provázené hypergamaglobulinémií a zánětlivými projevy. Praha: Grada 2022.
25. Dispenzieri A, Gertz MA, Therneau TM et al. Retrospective cohort study of 148 patients with polyclonal gammopathy. Mayo Clin Proc 2001; 76 (5): 476–487. doi: 10.4065/76.5.476.
26. Zhao EJ, Carruthers MN, Li CH et al. Conditions associated with polyclonal hypergammaglobulinemia in the IgG4-related disease era: a retrospective study from a hematology tertiary care center. Haematologica 2020; 105 (3): e121–e123. doi: 10.3324/haematol.2019.219725.
27. Andre M, Contis A, Berard AM. Etiological study of polyclonal hypergammaglobulinemia in a French cohort of hospitalized patients and proposal of a diagnostic aid algorithm: short title: polyclonal hypergammaglobulinemia in a French cohort of hospitalized patients. Sci Rep 2024; 14 (1): 31282. doi: 10.1038/s41598-024-82735-7.
28. Beuvon C, Martin M, Baillou C et al. Etiologies of polyclonal hypergammaglobulinemia: a scoping review. Eur J Intern Med 2021; 90 : 119–121. doi: 10.1016/j.ejim.2021.05.023.
29. Zhao EJ, Cheng CV, Mattman A et al. Polyclonal hypergammaglobulinaemia: assessment, clinical interpretation, and management. Lancet Haematol 2021; 8 (5): e365–e375. doi: 10.1016/S2352-3026 (21) 00056-9.
30. Kamiński B, Błochowiak K. Mikulicz’s disease and Küttner’s tumor as manifestations of IgG4-related diseases: a review of the literature. Reumatologia 2020; 58 (4): 243–250. doi: 10.5114/reum.2020.98437.
31. Sjögren H. Zur Kenntnis der Keratoconjunctivitis Sicca. Acta Ophthalmol 2009; 13 (1–2): 1–39. doi: 10.1111/j.1755-3768.1935.tb04186.x.
32. Ogawa Y, Takeuchi T, Tsubota K. Autoimmune epithelitis and chronic inflammation in Sjögren’s syndrome-related dry eye disease. Int J Mol Sci 2021; 22 (21): 11820. doi: 10.3390/ijms222111820.
33. Brabcová V. Sjögrenův syndrom. Cesk Dermatovenerol 2019; 9 (2): 86–90.
34. Kryštůfková O. Sjögrenův syndrom. Ces Revmatol 2017; 25 (1): 26–43.
35. Cui Y, Li L, Yin R et al. Depression in primary Sjögren’s syndrome: a systematic review and meta-analysis. Psychol Health Med 2018; 23 (2): 198–209. doi: 10.1080/13548506.2017.1339895.
36. Margaretten M. Neurologic manifestations of primary Sjögren syndrome. Rheum Dis Clin North Am 2017; 43 (4): 519–529. doi: 10.1016/j.rdc.2017.06.002.
37. Costa T, Rushton SP, Watson S et al. Depression in Sjögren’s syndrome mediates the relationship between pain, fatigue, sleepiness, and overall quality of life. Rheumatol Immunol Res 2023; 4 (2): 78–89. doi: 10.2478/rir-2023-0012.
38. Prak RF, Arends S, Verstappen GM et al. Fatigue in primary Sjögren’s syndrome is associated with an objective decline in physical performance, pain and depression. Clin Exp Rheumatol 2022; 40 (12): 2318–2328. doi: 10.55563/clinexprheumatol/70s6cs.
39. Deshpande V, Zen Y, Chan JK et al. Consensus statement on the pathology of IgG4-related disease. Mod Pathol 2012; 25 (9): 1181–1192. doi: 10.1038/modpathol.2012.72.
40. Chovancová Z, Filipenský P, Rotnáglová S et al. IgG4 immunoglobulin subclass and related pathological conditions or how to effectively imitate cancer disease. Klin Onkol 2022; 35 (1): 20–31.
41. Wallace ZS, Zhang Y, Perugino CA et al. Clinical phenotypes of IgG4-related disease: an analysis of two international cross-sectional cohorts. Ann Rheum Dis 2019; 78 (3): 406–412. doi: 10.1136/annrheumdis-2018-214603.
42. Kubíčková J, Zeleník K, Urban O et al. Manifestace IgG4 asociované nemoci v oblasti hlavy a krku. Otorinolaryngol Foniatr 2015; 64 (3): 163–167.
43. Hrnčíř Z, Laco J, Slezák R et al. Mikuliczova choroba s jednostranným exoftalmem – onemocnění se vztahem k IgG4. Ces Revmatol 2011; 19 (3): 125–130.
44. Hrnčíř Z, Laco J, Drahošová M et al. Biomarker IgG4 u Mikuliczovy choroby. Rheumatologia (Bratislava) 2011; 25 (3): 145.
45. Vojtová M, Balatková Z, Kalfert D et al. IgG4-asociovaná onemocnění v ORL oblasti – kazuistika. Otorinolaryngol Foniatr 2024; 73 (4): 270–273. doi: 10.48095/ccorl2024270.
46. Takano K, Yajima R, Kamekura R et al. Clinical utility of 18F-fluorodeoxyglucose/positron emission tomography in diagnosis of immunoglobulin G4-related sclerosing sialadenitis. Laryngoscope 2018; 128 (5): 1120–1125. doi: 10.1002/lary.26945.
47. Maslinska M, Kostyra-Grabczak K. Immunoglobulin G4 in primary Sjögren’s syndrome and IgG4-related disease – connections and dissimilarities. Front Immunol 2024; 15 : 1376723. doi: 10.3389/fimmu.2024.1376723.
48. Omar D, Chen Y, Cong Y et al. Glucocorticoids and steroid sparing medications monotherapies or in combination for IgG4-RD: a systematic review and network meta-analysis. Rheumatology (Oxford) 2020; 59 (4): 718–726. doi: 10.1093/rheumatology/kez380.
49. Yamamoto M, Yajima H, Takahashi H et al. Everyday clinical practice in IgG4-related dacryoadenitis and/or sialadenitis: results from the SMART database. Mod Rheumatol 2015; 25 (2): 199–204. doi: 10.3109/14397 595.2014.950036.
50. Eroglu E, Sipahioglu MH, Senel S, et al. Successful treatment of tubulointerstitial nephritis in immunoglobulin G4-related disease with rituximab: a case report. World J Clin Cases 2019; 7 (16): 2309–2315. doi: 10.12998/wjcc.v7.i16.2309.
51. Carruthers MN, Topazian MD, Khosroshahi A et al. Rituximab for IgG4-related disease: a prospective, open-label trial. Ann Rheum Dis 2015; 74 (6): 1171–1177. doi: 10.1136/annrheumdis-2014-206605.
52. Ebbo M, Grados A, Samson M et al. Long-term efficacy and safety of rituximab in IgG4-related disease: data from a French nationwide study of thirty-three patients. PLoS One 2017; 12 (9): e0183844. doi: 10.1371/journal.pone.0183844.
53. San S, Lin CD, Tsai ST et al. Immunoglobulin G4-related disease presented as recurrent otitis media and mixed hearing loss treated with cyclophosphamide and rituximab: a case report. Arch Rheumatol 2018; 34 (2): 233–237. doi: 10.5606/ArchRheumatol.2019.7178.
54. Dong Y, Zhang L, Nong L et al. Effectiveness of rituximab-containing treatment regimens in idiopathic multicentric Castleman disease. Ann Hematol 2018; 97 (9): 1641–1647. doi: 10.1007/s00277-018-3347-0.
55. Quattrocchio G, Barreca A, Demarchi A et al. IgG4-related kidney disease: the effects of a Rituximab-based immunosuppressive therapy. Oncotarget 2018; 9 (30): 21337–21347. doi: 10.18632/oncotarget.25095.
56. Benad M, Koschel D, Herrmann K et al. Effects of cyclophosphamide and rituximab in patients with connective tissue diseases with severe interstitial lung disease. Clin Exp Rheumatol 2022; 40 (3): 483–488. doi: 10.55563/clinexprheumatol/o5t1f7.
57. Lanzillotta M, Mapelli P, Dagna L et al. B-cell depletion with obinutuzumab for the treatment of IgG4-related disease. Eur J Intern Med 2023; 116 : 155–156. doi: 10.1016/j.ejim.2023.07.019.
58. Sun H, Zeng X, Li Y et al. Successful remission induction of IgG4-related ophthalmic disease by obinutuzumab therapy: a retrospective study of 8 patients. Eye (Lond) 2024; 38 (4): 723–729. doi: 10.1038/s41433-023-02758-8.
59. Ginthör NE, Artinger K, Pollheimer MJ et al. Membranous nephropathy associated with immunoglobulin G4-related disease successfully treated with obinutuzumab. Clin Kidney J 2021; 15 (3): 564–566. doi: 10.1093/ckj/sfab250.
60. Frampton JE. Inebilizumab: first approval. Drugs 2020; 80 (12): 1259–1264. doi: 10.1007/s40265-020-01370-4.
61. Nie T, Blair HA. Inebilizumab: a review in neuromyelitis optica spectrum disorder. CNS Drugs 2022; 36 (10): 1133–1141. doi: 10.1007/s40263-022-00949-7.
62. Stone JH, Khosroshahi A, Zhang W et al. MITIGATE Trial investigators. Inebilizumab for treatment of IgG4-related disease. N Engl J Med 2025; 392 (12): 1168–1177. doi: 10.1056/NEJMoa2409712.
63. Li S, Gao Y, He Y, Zhang Z. A case report of AQP4-IgG--seropositive refraktory neuromyelitis optica spectrum disorder patient with Sjögren’s syndrome and pancytopenia treated with inebilizumab. Front Neurol 2024; 15 : 1371515. doi: 10.3389/fneur.2024.1371515.
64. Marinho A, Delgado Alves J, Fortuna J et al. Biological therapy in systemic lupus erythematosus, antiphospholipid syndrome, and Sjögren’s syndrome: evidence - and practice-based guidance. Front Immunol 2023; 14 : 1117699. doi: 10.3389/fimmu.2023.1117699.
65. Bowman SJ, Everett CC, O’Dwyer JL et al. Randomized controlled trial of rituximab and cost-effectiveness analysis in treating fatigue and oral dryness in primary Sjögren’s syndrome. Arthritis Rheumatol 2017; 69 (7): 1440–1450. doi: 10.1002/art.40093.
66. Gottenberg JE, Cinquetti G, Larroche C et al. Efficacy of rituximab in systemic manifestations of primary Sjögren’s syndrome: results in 78 patients of the AutoImmune and Rituximab registry. Ann Rheum Dis 2013; 72 (6): 1026–1031. doi: 10.1136/annrheumdis-2012 - 202293.
67. Tony HP, Burmester G, Schulze-Koops H et al. Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: experience from a national registry (GRAID). Arthritis Res Ther 2011; 13 (3): R75. doi: 10.1186/ar3337.
68. Ramos-Casals M, Brito-Zerón P, Bombardieri S et al. EULAR recommendations for the management of Sjögren’s syndrome with topical and systemic therapies. Ann Rheum Dis 2020; 79 (1): 3–18. doi: 10.1136/annrheumdis-2019-216114.
69. Souza FB, Porfírio GJ, Andriolo BN et al. Rituximab effectiveness and safety for treating primary Sjögren’s syndrome (pSS): systematic review and meta-analysis. PLoS One 2016; 11 (3): e0150749. doi: 10.1371/journal.pone. 0150749.
70. Chen YH, Wang XY, Jin X et al. Rituximab therapy for primary Sjögren’s syndrome. Front Pharmacol 2021; 12 : 731122. doi: 10.3389/fphar.2021.731122.
71. St Clair EW, Levesque MC, Prak ET al. Rituximab therapy for primary Sjögren’s syndrome: an open-label clinical trial and mechanistic analysis. Arthritis Rheum 2013; 65 (4): 1097–1106. doi: 10.1002/art.37850.
72. Carubbi F, Cipriani P, Marrelli A et al. Efficacy and safety of rituximab treatment in early primary Sjögren’s syndrome: a prospective, multi-center, follow-up study. Arthritis Res Ther 2013; 15 (5): R172. doi: 10.1186/ar4359.
73. Pezot M, Nocturne G, Belkhir R et al. Obinutuzumab in patients with Sjogren’s disease immunised against rituximab. Ann Rheum Dis 2024; 83 (3): 407–408. doi: 10.1136/ard-2023-224999.
74. Gaudêncio M, Parente C, Lameiras AC et al. Mixed cryoglobulinaemia vasculitis treated with obinutuzumab in a patient allergic to rituximab. Eur J Case Rep Intern Med 2021; 8 (11): 003019. doi: 10.12890/2021_003019.
75. Mariette X, Barone F, Baldini C et al. A randomized, phase II study of sequential belimumab and rituximab in primary Sjögren’s syndrome. JCI Insight 2022; 7 (23): e163030. doi: 10.1172/jci.insight.163030.
76. Němec P. Revmatologie pro praxi. Praha: Grada Publishing 2021.
77. Adam Z, Zeman D, Chodacki A et al. Therapy of Castleman’s disease with siltuximab – case report and review of literature. Klin Onkol 2023; 36 (4): 320–329.
78. Carruthers M, Khosroshahi A, Augustin T et al. The diagnostic utility of serum IgG4 concentrations in IgG4--related disease. Ann Rheum Dis 2015; 74 (1): 14–18. doi: 10.1136/annrheumdis-2013-204907.
79. Wallace ZS, Mattoo H, Carruthers M et al. Plasmablasts as a biomarker for IgG4-related disease, independent of serum IgG4 concentrations. Ann Rheum Dis 2015; 74 (1): 190–195. doi: 10.1136/annrheumdis-2014-205233.
80. Němec P, Řehák Z, Fabián P et al. The use of positron emission tomography (18F-FDG PET) in diagnosing chronic periaortitis. Vnitr Lek 2008; 54 (11): 1093–1099.
Don‘t have an account? Create new account
Enter the email address that you registered with. We will send you instructions on how to set a new password.
